Autopsy report · NCT03678480

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

“Corporate decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

HighTide Therapeutics (Hong Kong) Limited

Sponsor type

Industry

Conditions

Primary Sclerosing Cholangitis; Cholangitis; Cholangitis, Sclerosing; Bile Duct Diseases; Biliary Tract Diseases; Digestive System Diseases

Interventions

HTD1801; Ursodeoxycholic Acid

Participants

0

Trials that died the same way

• Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
  “Company decision” (90% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (88% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (86% match in meaning)
• A Clinical Trial to Test the Effect of an Experimental Mouth Rinse on Gum Disease
  “Business Decision” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.